Therapeutic Antibodies

Question 1

Alemtuzumab (target, use)

Answer 1

CD52 - CLL

Question 2

Bevacizumab (target, 2 uses)

Answer 2

VEGF, Colorectal cancer, RCC

Question 3

Cetuximab (target, 2 uses)

Answer 3

EGFR, Stage IV colorectal ca, H&N cancer

Question 4

Rituximab (target, 4 uses)

Answer 4

CD20 - Bcell non-Hodgkin lymphoma, CLL, RA, ITP

Question 5

Trastuzumab (target, use)

Answer 5

HER2/neu - HER2+ Breast Cancer

Question 6

Adalimumab, infliximab (target, uses)

Answer 6

Soluble TNF-alpha. For Seronegatives arthropathies - IBD, rheumatoid arthritis, AS, psoriasis

Question 7

Etancercept

Answer 7

Decoy TNF-alpha R, not really monoclonal Ab. But like adalimumab and infliximab

Question 8

Eculizumab (target, use)

Answer 8

Complement protein C5, PNH

Question 9

Natalizumab (target, 2 uses, risk)

Answer 9

alpha4-integrin (WBC adhesion)
MS, CD
Risk of PML in patients with JC virus

Question 10

Abciximab (target, use)

Answer 10

Platelet glycoproteins IIb/IIIa

Antiplatelet agent to prevent ischemic complications from percutaneous coronary intervention like stents and shit

Question 11

Denosumab (target, use)

Answer 11

RANKL

Osteoporosis, inhibits osteoclast maturation by mimicking osteoprotegerin

Question 12

Digoxin immune Fab (target, use)

Answer 12

Digoxin

Antidote for Digoxin toxicity

Question 13

Omalizumab (target, use)

Answer 13

IgE, prevents IgE binding to FcepsilonR?

To treat allergic asthma

Question 14

Palivizumab (target, use)

Answer 14

RSV F protein, for RSV prophylaxis for high risk infants

Question 15

Ranibizumab, bevacizumab (target, use)

Answer 15

VEGF

Neovascular age-related macular degeneration